For example, IC50 of Vincristine, a common chemotherapeutic agent of many combination regimens for lymphoid malignancies, displayed an obvious difference in the two groups, indicating that high expression of eIF3a may be correlated with higher sensitivity to Vincristine in DLBCL (Fig. 7C). This evidence concerns the gene EIF3A and diffuse large B-cell lymphoma.